Hepatitis C Virus (HCV) is a significant global health concern, affecting millions of individuals worldwide. The virus is an enveloped, positive-sense single-stranded RNA virus belonging to the Hepacivirus genus within the Flaviviridae family . HCV infection can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, making it a critical target for vaccine development .
The HCV genome encodes a single polyprotein, which is processed into ten mature proteins, including three structural proteins (core, E1, E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) . The structural proteins are essential for the formation of the viral particle, while the non-structural proteins are involved in viral replication and assembly .
The Mosaic Antigen-B Recombinant is a synthetic construct designed to enhance the immune response against HCV. It incorporates multiple epitopes from different HCV proteins to create a broad and robust immune response . This approach aims to overcome the high genetic diversity of HCV, which poses a significant challenge for vaccine development .
The primary function of the Mosaic Antigen-B Recombinant is to elicit both humoral and cellular immune responses. By presenting multiple epitopes, it can stimulate a wide range of immune cells, including B cells and T cells . This broad activation is crucial for generating a strong and long-lasting immune response capable of neutralizing diverse HCV strains .
The Mosaic Antigen-B Recombinant has several potential applications in the field of HCV research and vaccine development. It can be used as a component of DNA vaccines, recombinant protein vaccines, and virus-like particle (VLP) vaccines . Additionally, it holds promise for use in therapeutic vaccines aimed at treating chronic HCV infections .